Literature DB >> 19641321

A 2008 questionnaire-based survey of gastroesophageal reflux disease and related diseases by physicians in East Asian countries.

Yasuhiro Fujiwara1, Shin-ichi Takahashi, Tetsuo Arakawa, Jose D Sollano, Qi Zhu, Udom Kachintorn, Abdul Aziz Rani, Ki-Baik Hahm, Takashi Joh, Yoshikazu Kinoshita, Takayuki Matsumoto, Yuji Naito, Koji Takeuchi, Kenji Furuta, Akira Terano.   

Abstract

BACKGROUND/AIMS: Gastroesophageal reflux disease (GERD) is a common gastrointestinal disease. This study was designed to examine current epidemiology, diagnosis, management, and treatment of patients diagnosed with GERD by surveying physicians in several East Asian countries.
METHODS: A questionnaire-based survey was completed in six countries including China, Indonesia, Japan, Korea, the Philippines, and Thailand between July 2008 and December 2008.
RESULTS: In total, 876 physicians participated in the study. Most physicians in all countries, except Japan, frequently used international guidelines for the care of GERD patients, whereas approximately half of Japanese physicians did not use such guidelines. GERD was common among many patients, but Barrett's esophagus, particularly the long-segmental type, was rare. The incidence of esophageal cancer, particularly adenocarcinoma, was high in China, but low in other countries. Most physicians diagnosed GERD based on symptoms, followed by endoscopy in Japan and Korea, or in other countries, by the proton-pump inhibitor (PPI) test. Heartburn was recognized as the chief complaint in all countries except Korea. Most physicians in all countries used PPI as the first-line of treatment for GERD. Increasing the PPI dose was the treatment of choice for PPI-refractory erosive esophagitis in Korea, the Philippines, and Thailand. In contrast, in other countries, physicians used a combination of PPI and other drugs to treat PPI-refractory erosive esophagitis. Prescription of antidepressant drugs increased for PPI-refractory nonerosive reflux disease compared with PPI-refractory erosive esophagitis.
CONCLUSION: The findings in the present survey are useful to understand the current epidemiology, diagnosis, and treatment of GERD in East Asian countries. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2009        PMID: 19641321     DOI: 10.1159/000226088

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  14 in total

Review 1.  Proton pump inhibitor for non-erosive reflux disease: a meta-analysis.

Authors:  Ji-Xiang Zhang; Meng-Yao Ji; Jia Song; Hong-Bo Lei; Shi Qiu; Jing Wang; Ming-Hua Ai; Jun Wang; Xiao-Guang Lv; Zi-Rong Yang; Wei-Guo Dong
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

Review 2.  Natural history of Barrett's esophagus.

Authors:  Rao Milind; Stephen E Attwood
Journal:  World J Gastroenterol       Date:  2012-07-21       Impact factor: 5.742

3.  Medium-Term Outcomes after Reversal of Roux-en-Y Gastric Bypass.

Authors:  Gustavo Andrés Arman; J Himpens; R Bolckmans; D Van Compernolle; R Vilallonga; G Leman
Journal:  Obes Surg       Date:  2018-03       Impact factor: 4.129

Review 4.  Systematic review of the epidemiology of gastroesophageal reflux disease in Japan.

Authors:  Yoshikazu Kinoshita; Kyoichi Adachi; Michio Hongo; Ken Haruma
Journal:  J Gastroenterol       Date:  2011-06-22       Impact factor: 7.527

5.  Lifestyle factors affecting gastroesophageal reflux disease symptoms: a cross-sectional study of healthy 19864 adults using FSSG scores.

Authors:  Nobutake Yamamichi; Satoshi Mochizuki; Itsuko Asada-Hirayama; Rie Mikami-Matsuda; Takeshi Shimamoto; Maki Konno-Shimizu; Yu Takahashi; Chihiro Takeuchi; Keiko Niimi; Satoshi Ono; Shinya Kodashima; Chihiro Minatsuki; Mitsuhiro Fujishiro; Toru Mitsushima; Kazuhiko Koike
Journal:  BMC Med       Date:  2012-05-03       Impact factor: 8.775

6.  A Multicenter, Randomized, Open-Label Trial: Efficacy of Once-Daily Versus Twice-Daily Double-Dose Rabeprazole on Refractory Gastroesophageal Reflux Disease-Related Symptoms and Quality of Life.

Authors:  Akira Mizuki; Masayuki Tatemichi; Terue Sakakibara; Yukihiko Miura; Shigeyuki Zeki; Mitsuru Ohata; Kenji Matsuo; Fumio Kawamura; Hiroshi Nagata
Journal:  Curr Ther Res Clin Exp       Date:  2016-11-25

7.  Predictable Marker for Regression of Barrett's Esophagus by Proton Pump Inhibitor Treatment in Korea.

Authors:  Hyun Jin Jo; Hye Seung Lee; Nayoung Kim; Ryoung Hee Nam; Hyun Chang; Min Soo Kim; Sung Eun Kim; Jane C Oh; Dong Ho Lee; Hyun Chae Jung
Journal:  J Neurogastroenterol Motil       Date:  2013-04-16       Impact factor: 4.924

8.  Upper gastrointestinal cancer and reflux disease.

Authors:  Jin-Jo Kim
Journal:  J Gastric Cancer       Date:  2013-06-25       Impact factor: 3.720

9.  Review of Clinical Spectrum of Gastroesophageal Reflux Disease in a General Population; A Study from South-East Iran.

Authors:  Sodaif Darvishmoghadam; Mohammad Javad Zahedi; Mohammad Mehdi Hayatbakhsh Abbasi; Ali Akbar Haghdoost; Mahdieh Khalilyzade; Elham Karimi Goughari
Journal:  Middle East J Dig Dis       Date:  2016-10

10.  Esophageal Body Motility for Clinical Assessment in Patients with Refractory Gastroesophageal Reflux Symptoms.

Authors:  Liuqin Jiang; Bixing Ye; Ying Wang; Meifeng Wang; Lin Lin
Journal:  J Neurogastroenterol Motil       Date:  2017-01-30       Impact factor: 4.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.